| scholarly article | Q13442814 |
| P50 | author | Magdalena Rausch | Q106624513 |
| Patrycja Nowak-Sliwinska | Q90944624 | ||
| P2093 | author name string | Andrea Weiss | |
| Andrei Rotari | |||
| Joanna Achkhanian | |||
| P2860 | cites work | Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer | Q91995955 |
| Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma | Q92819977 | ||
| Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression | Q93000839 | ||
| Starving cancer cells to death | Q114829030 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| The PI3K/AKT Pathway and Renal Cell Carcinoma | Q26800216 | ||
| Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition. | Q27329647 | ||
| The great escape; the hallmarks of resistance to antiangiogenic therapy. | Q27693262 | ||
| First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors | Q27853088 | ||
| Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia | Q29614280 | ||
| MAP kinase signalling pathways in cancer | Q29615542 | ||
| Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers | Q30514153 | ||
| Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients | Q33588739 | ||
| Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy | Q33854836 | ||
| Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials | Q34032864 | ||
| Nanotubular highways for intercellular organelle transport | Q34298770 | ||
| Cell metabolism: an essential link between cell growth and apoptosis | Q34440592 | ||
| A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer | Q35171100 | ||
| BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-A | Q35664516 | ||
| Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. | Q35703000 | ||
| Three Dimensional Culture of Human Renal Cell Carcinoma Organoids | Q35759222 | ||
| A streamlined search technology for identification of synergistic drug combinations | Q36101810 | ||
| Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma | Q36287995 | ||
| A novel p21 attenuator which is structurally related to sorafenib | Q36677729 | ||
| Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model | Q36821344 | ||
| Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma | Q37414808 | ||
| Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity | Q37657640 | ||
| Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma | Q37672483 | ||
| Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma | Q37752357 | ||
| Tyrosine kinase signaling in kidney glomerular podocytes | Q37903259 | ||
| Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects | Q38386352 | ||
| Role of the tumor stroma in resistance to anti-angiogenic therapy. | Q38828196 | ||
| mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma | Q38908811 | ||
| Sunitinib in kidney cancer: 10 years of experience and development. | Q39038214 | ||
| Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells | Q39167898 | ||
| Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models | Q39184115 | ||
| AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family | Q39389469 | ||
| Optimization of drug combinations using Feedback System Control | Q40109230 | ||
| Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma | Q43109173 | ||
| Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy. | Q47099537 | ||
| Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors. | Q47204017 | ||
| Tunneling nanotubes: A versatile target for cancer therapy | Q47348197 | ||
| Elucidating mechanisms of sunitinib resistance in renal cancer: an integrated pathological-molecular analysis | Q49687781 | ||
| Starvation, Stress Resistance, and Cancer | Q49793201 | ||
| Combination therapies for patients with metastatic renal cell carcinoma. | Q50030018 | ||
| Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes | Q50345931 | ||
| High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells. | Q50487103 | ||
| Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. | Q52584350 | ||
| Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. | Q52644831 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. | Q54500899 | ||
| A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. | Q55208909 | ||
| Klotho inhibits EGF-induced cell migration in Caki-1 cells through inactivation of EGFR and p38 MAPK signaling pathways. | Q55253540 | ||
| In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition. | Q55487416 | ||
| Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial | Q57949267 | ||
| The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study | Q58103455 | ||
| Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells | Q58790703 | ||
| Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial | Q59571527 | ||
| Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy | Q60918204 | ||
| Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma | Q64063031 | ||
| Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines | Q64118758 | ||
| Stress-induced tunneling nanotubes support treatment adaptation in prostate cancer. | Q64890511 | ||
| Investigation of Metabolomic Changes in Sunitinib-Resistant Human Renal Carcinoma 786-O Cells by Capillary Electrophoresis-Time of Flight Mass Spectrometry | Q88242912 | ||
| Current Trends in Multidrug Optimization: An Alley of Future Successful Treatment of Complex Disorders | Q89353420 | ||
| Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies | Q89393258 | ||
| Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering | Q90944626 | ||
| Cell communication by tunneling nanotubes: Implications in disease and therapeutic applications | Q91397065 | ||
| Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | Q91700806 | ||
| Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma | Q91991470 | ||
| P921 | main subject | renal cell carcinoma | Q1164529 |
| P577 | publication date | 2020-05-22 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma |
| Q123351242 | Advanced in vitro models for renal cell carcinoma therapy design |
| Q106957867 | Characterization of Renal Cell Carcinoma Heterotypic 3D Co-Cultures with Immune Cell Subsets |
| Q111381875 | Cytoplasmic Localization Isoform of Cyclin Y Enhanced the Metastatic Ability of Lung Cancer via Regulating Tropomyosin 4 |
| Q108003603 | Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma |
| Q111381876 | FGFR-TKI resistance in cancer: current status and perspectives |
| Q99614963 | Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment |
| Q123350965 | Modulation of lncRNA links endothelial glycocalyx to vascular dysfunction of tyrosine kinase inhibitor |
| Q107270365 | Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells |
| Q123351319 | Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer |
| Q101130204 | Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance |
Search more.